$NOVN First demonstration of antiviral effect of nitric oxide-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium - Company believes preclinical results demonstrate high potential for clinical translation - Company plans to initiate Chemistry, Manufacturing, and Controls (CMC) work to develop intranasal formulation of berdazimer sodium for use in coronavirus program
  • 2